Back to Search
Start Over
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease
- Source :
- Nature reviews. Gastroenterology & hepatology, Nature reviews. Gastroenterology & hepatology, Nature Publishing Group, 2009-, 2021, 18 (12), pp.857-873. ⟨10.1038/s41575-021-00492-8⟩, Nature Reviews. Gastroenterology & Hepatology
- Publication Year :
- 2021
- Publisher :
- Springer Science and Business Media LLC, 2021.
-
Abstract
- Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events. Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based Guideline were to summarize available evidence and to provide practical recommendations regarding epidemiological aspects, prevention and drug-related risks of venous and arterial thrombotic events in patients with IBD. A virtual meeting took place in May 2020 involving 14 international IBD experts and 3 thrombosis experts from 12 countries. Proposed statements were voted upon in an anonymous manner. Agreement was defined as at least 75% of participants voting as ‘fully agree’ or ‘mostly agree’ with each statement. For each statement, the level of evidence was graded according to the Scottish Intercollegiate Guidelines Network (SIGN) grading system. Consensus was reached for 19 statements. Patients with IBD harbour an increased risk of venous and arterial thrombotic events. Thromboprophylaxis is indicated during hospitalization of any cause in patients with IBD. Disease activity is a modifiable risk factor in patients with IBD, and physicians should aim to achieve deep remission to reduce the risk. Exposure to steroids should be limited. Antitumour necrosis factor agents might be associated with a reduced risk of thrombotic events.<br />Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events. This Evidence-Based Guideline presents an international consensus on the prevention of venous and arterial thrombotic events in patients with IBD, and includes 19 recommendations for clinical practice.
- Subjects :
- Evidence-Based Guidelines
medicine.medical_specialty
[SDV]Life Sciences [q-bio]
International Cooperation
Settore MED/12 - GASTROENTEROLOGIA
education
Anti-Inflammatory Agents
MEDLINE
030204 cardiovascular system & hematology
Risk Assessment
Inflammatory bowel disease
03 medical and health sciences
0302 clinical medicine
Fibrinolytic Agents
Risk Factors
Epidemiology
Humans
Medicine
In patient
Risk factor
Intensive care medicine
Hepatology
business.industry
Patient Acuity
Gastroenterology
Thrombosis
Guideline
Evidence-based medicine
Inflammatory Bowel Diseases
medicine.disease
digestive system diseases
3. Good health
Hospitalization
Cardiovascular diseases
030211 gastroenterology & hepatology
business
Subjects
Details
- ISSN :
- 17595053 and 17595045
- Volume :
- 18
- Database :
- OpenAIRE
- Journal :
- Nature Reviews Gastroenterology & Hepatology
- Accession number :
- edsair.doi.dedup.....88c0deac8c21cbd7248c13c4be64b948